Understanding Proliferative Diabetic Retinopathy (PDR)

Proliferative diabetic retinopathy (PDR) represents the most advanced stage of diabetic eye disease and is a leading cause of preventable blindness among working-age adults. The condition arises when chronic hyperglycemia damages the tiny blood vessels that nourish the retina. Over time, these vessels become occluded, leading to areas of retinal ischemia (oxygen deprivation). In response, the retina releases vascular endothelial growth factor (VEGF), a signaling protein that stimulates the growth of new, abnormal blood vessels on the surface of the retina and the optic disc. These fragile vessels are prone to hemorrhage, causing vitreous hemorrhage, and can lead to tractional retinal detachment through subsequent scar tissue formation.

Key risk factors for progression to PDR include poor glycemic control, long duration of diabetes, concomitant hypertension, dyslipidemia, and pregnancy. The incidence of PDR is increasing globally, paralleling the rise in type 2 diabetes. Approximately 50% of patients with type 1 diabetes and 10–15% of those with type 2 diabetes develop PDR within 15 years of diagnosis. Without timely intervention, the natural course of PDR frequently results in severe, irreversible vision loss.

Clinical note: Early detection through regular dilated fundus examinations is critical because PDR can remain asymptomatic until advanced complications occur. The American Diabetes Association recommends annual screening for patients with type 2 diabetes at diagnosis and for those with type 1 diabetes after five years.

Anti-VEGF Injections: Mechanism and Clinical Use

Anti-VEGF therapy has revolutionized the management of PDR over the past two decades. These agents are monoclonal antibodies or antibody fragments that bind directly to VEGF molecules, preventing their interaction with endothelial cell receptors. By neutralizing VEGF, the drugs inhibit the formation and progression of neovascularization, reduce vascular permeability, and promote the regression of existing abnormal vessels.

Common Anti-VEGF Agents

  • Bevacizumab (Avastin): A full-length monoclonal antibody approved for cancer but used off-label in ophthalmology. It is significantly less expensive than other options and has a robust evidence base from multicenter trials like the DRCR.net Protocol T.
  • Ranibizumab (Lucentis): A smaller antibody fragment designed for intraocular use. It offers high affinity for VEGF-A and is approved by the FDA for diabetic macular edema and diabetic retinopathy.
  • Aflibercept (Eylea): A fusion protein that acts as a VEGF trap, binding multiple isoforms of VEGF and placental growth factor (PlGF). It often allows for extended dosing intervals compared with ranibizumab and bevacizumab.
  • Brolucizumab (Beovu): A newer single-chain antibody fragment with a smaller molecular weight, enabling higher molar dosing. It has shown potential for extended durability but carries a slightly higher risk of intraocular inflammation.

Treatment Regimens

Anti-VEGF therapy for PDR is typically administered as an intravitreal injection in an office setting. The standard loading phase consists of monthly injections for four to six doses, followed by a treat-and-extend or pro re nata (PRN) protocol based on clinical response. In randomized controlled trials, patients receiving ranibizumab or aflibercept for PDR required an average of 7–9 injections in the first year, with a reduction in frequency in subsequent years.

The DRCR.net Protocol S compared ranibizumab with panretinal photocoagulation (PRP) for PDR and found that anti-VEGF therapy was non-inferior to laser for preventing vision loss over two years. Moreover, anti-VEGF treatment resulted in better visual acuity outcomes and a lower rate of vitreous hemorrhage and neovascular glaucoma. These findings established anti-VEGF as a first-line option for many patients with PDR, particularly those with center-involved diabetic macular edema (DME) in the same eye.

Advantages of Anti-VEGF Injections

  • Rapid onset of action – many patients experience regression of neovascularization within weeks.
  • Potential for visual acuity improvement, especially when DME is present.
  • Less damage to the peripheral retina compared with PRP, preserving night vision and peripheral fields.
  • No risk of laser burn-induced complications such as exudative retinal detachment or choroidal effusion.

Disadvantages and Considerations

  • Requires repeated office visits and injections, which can be burdensome for patients and caregivers.
  • High cumulative cost, particularly for branded medications, though bevacizumab remains a cost-effective alternative.
  • Risk of injection-related adverse events: endophthalmitis (approximately 1 in 2,000–3,000 cases), retinal detachment, elevated intraocular pressure, and intraocular hemorrhage.
  • Treatment burden may lead to non-adherence and subsequent recurrence of neovascularization.
  • Some patients show incomplete response or resistance, requiring switch to an alternative agent or combination with laser.

Laser Therapy for PDR: Principles and Practice

Laser photocoagulation has been the cornerstone of PDR treatment since the Diabetic Retinopathy Study (DRS) in the 1970s first demonstrated its efficacy. The traditional approach is panretinal photocoagulation (PRP), which involves placing 1,200–1,600 argon laser burns in a scatter pattern across the peripheral retina. The therapeutic mechanism is twofold: laser ablation destroys ischemic retinal tissue that produces VEGF, and it also improves oxygen diffusion from the choroid to the inner retina, reducing the hypoxic drive for neovascularization.

Technique and Modern Variations

PRP is typically performed in two to four sessions to minimize pain and reduce the risk of exudative retinal detachment. Advanced laser technologies, such as pattern scan laser (PASCAL) and navigated laser (Navilas), allow for faster, more precise treatment with shorter pulse durations, thereby reducing pain and collateral damage. In recent years, targeted retinal photocoagulation (TRP) has emerged, focusing laser burns specifically on areas of non-perfusion identified by widefield fluorescein angiography, potentially sparing healthy retina.

Efficacy and Outcomes

The Early Treatment Diabetic Retinopathy Study (ETDRS) demonstrated that prompt PRP reduces the risk of severe vision loss from PDR by 50–60%. For patients with high-risk PDR (defined by the presence of neovascularization of the disc or vitreous hemorrhage), laser therapy remains a highly effective and durable intervention. Many patients achieve long-term stabilization without the need for ongoing treatment, which is a significant advantage over anti-VEGF therapy.

Advantages of Laser Therapy

  • One-time or limited treatment sessions – typically completed within 1–4 visits.
  • Long-term stability – regression of neovascularization persists years after treatment in many cases.
  • Lower long-term cost compared with ongoing injection therapy.
  • No risk of infection or injection-related complications.
  • Suitable for patients who cannot comply with frequent follow-ups, such as those in remote areas.

Disadvantages and Side Effects

  • Peripheral visual field loss: PRP permanently destroys portions of the peripheral retina, leading to constriction of the visual field, which can affect driving and mobility. The extent of field loss correlates with the number of laser burns.
  • Night vision difficulties: Patients often report decreased scotopic sensitivity and delayed dark adaptation.
  • Exacerbation of diabetic macular edema: PRP can worsen pre-existing DME, which is why many clinicians now combine laser with anti-VEGF or perform anti-VEGF first.
  • Pain during and after treatment: Although mitigated by topical anesthesia and newer laser technologies, PRP can still be uncomfortable.
  • Limited effect on visual acuity: Laser therapy does not improve central vision; its primary goal is to prevent further vision loss.

Comparative Effectiveness: Anti-VEGF vs. Laser Therapy

Several large-scale clinical trials have directly compared anti-VEGF monotherapy with PRP for PDR. The DRCR.net Protocol S randomized 394 eyes with PDR (with or without DME) to receive ranibizumab or PRP. At two years, mean visual acuity change was +2.8 letters in the ranibizumab group versus +0.2 letters in the PRP group, a statistically significant difference favoring anti-VEGF. Additionally, the ranibizumab group had fewer vitreous hemorrhages and less need for vitrectomy. However, by five years, the difference in visual acuity was no longer significant, suggesting that PRP's effects are durable while anti-VEGF benefits may wane if treatment is not maintained.

The Protocol S also assessed peripheral visual function using Goldmann perimetry. Patients treated with PRP experienced a mean 1.8-dB reduction in peripheral field sensitivity, whereas those receiving ranibizumab showed minimal change. This finding underscores the field-sparing advantage of anti-VEGF therapy.

A Cochrane meta-analysis published in 2023 evaluated 18 randomized trials including over 2,500 participants. The authors concluded that anti-VEGF agents probably improve visual acuity and reduce the risk of vitreous hemorrhage compared with PRP at one to two years, but the quality of evidence was moderate due to heterogeneity in dosing regimens and outcome measures. Importantly, there was insufficient evidence to determine long-term (beyond five years) differences in severe vision loss or quality of life.

For patients with DME in addition to PDR, anti-VEGF therapy is clearly superior because it addresses both conditions simultaneously. In contrast, PRP alone may worsen DME and requires adjunctive anti-VEGF or steroid treatment.

Combination Therapy and Individualized Decision-Making

Many retina specialists now favor an individualized approach rather than a one-size-fits-all paradigm. Combination therapy—using both anti-VEGF injections and laser—can be beneficial in specific scenarios:

  • High-risk PDR with vitreous hemorrhage: Initial intravitreal anti-VEGF often causes rapid regression of bleeding vessels, clearing the media for subsequent PRP.
  • Non-adherent patients: A few laser sessions may provide a safety net if the patient misses future injections.
  • Incomplete response to anti-VEGF: Adding focal or sectoral laser to areas of persistent neovascularization can achieve regression.
  • Neovascular glaucoma: PRP combined with anti-VEGF and glaucoma surgery is the standard of care.

The timing and sequence of combination therapy matter. The DRCR.net Protocol W tested early PRP (before the development of high-risk PDR) versus deferral and found no benefit; therefore, laser is not routinely used for non-high-risk PDR. For patients already on anti-VEGF, one can consider "rescue PRP" if neovascularization fails to regress after six monthly injections.

Treatment Selection Algorithm

A practical algorithm based on current evidence and expert consensus:

  1. Assess for DME: If center-involved DME is present, initiate anti-VEGF therapy regardless of PDR severity. Delay PRP until DME is controlled.
  2. High-risk PDR without DME: Offer either anti-VEGF or PRP after discussing trade-offs. Anti-VEGF is favored for patients who are reliable with follow-up and value peripheral vision; PRP is favored for those who prefer fewer visits and lower long-term cost.
  3. Vitreous hemorrhage: Start with anti-VEGF; consider vitrectomy if hemorrhage does not clear or if retinal detachment develops.
  4. Bilateral disease: Often treat one eye with anti-VEGF and the other with PRP to compare response, although this is not always feasible.

Patient Considerations and Quality of Life

Treatment choice must account for the patient's lifestyle, occupation, travel distance to the clinic, and ability to adhere to follow-up. Anti-VEGF injections require monthly visits initially, which can disrupt work and family responsibilities. In contrast, laser therapy is completed over fewer sessions but may cause permanent peripheral vision loss that affects night driving and recreational activities.

Cost is another major factor. In the United States, Medicare and most insurers cover both treatments, but patient copays for brand-name anti-VEGF drugs can be substantial. Bevacizumab offers a lower-cost alternative, but compounding and preparation may limit its availability in some settings. Laser therapy, after the initial procedure, incurs no further treatment cost unless complications arise.

Psychological burden should not be overlooked. Anti-VEGF patients often report anxiety about repeated eye injections, while laser patients may struggle with adaptation to constricted visual fields. Comprehensive patient education and shared decision-making are essential to optimize outcomes and satisfaction.

Future Directions and Emerging Therapies

The field continues to evolve rapidly. Longer-acting anti-VEGF formulations, such as faricimab (Vabysmo) which targets both VEGF-A and Ang-2, have shown extended durability in phase 3 trials, with many patients able to maintain 12- or 16-week dosing intervals. Port delivery systems (e.g., ranibizumab port delivery system) allow continuous drug release for up to 24 months, potentially eliminating the need for frequent injections.

Gene therapy approaches are also in early clinical development. By transducing retinal cells to produce anti-VEGF proteins endogenously, a one-time treatment could theoretically provide lifelong protection. While still investigational, these advances promise to reduce treatment burden and improve long-term outcomes for patients with PDR.

Photocoagulation techniques continue to improve. Subthreshold micropulse laser and selective retina therapy (SRT) offer the potential for vascular remodeling without damaging the retinal pigment epithelium, possibly sparing peripheral vision. These treatments are not yet standard for PDR but may play a role in the future.

Conclusion

Both anti-VEGF injections and laser therapy remain essential tools in the management of proliferative diabetic retinopathy. Anti-VEGF therapy provides rapid regression of neovascularization, potential visual improvement, and preservation of peripheral visual field, at the cost of frequent injections and higher ongoing expenses. Laser therapy offers durable regression with fewer visits but permanently sacrifices some peripheral vision and does not improve central acuity.

The choice between them is not binary; many patients benefit from a tailored combination approach. Ongoing clinical trials, such as the DRCR.net Protocol AA, continue to refine treatment algorithms. Patients with PDR should work closely with a retina specialist to select a strategy that aligns with their ocular condition, personal preferences, and lifestyle. Regardless of the modality chosen, early detection and adherence to follow-up remain the most critical factors in preserving sight.

Key resource: For the latest evidence-based guidelines, consult the American Academy of Ophthalmology's Preferred Practice Pattern for diabetic retinopathy (AAO PPP) and the National Eye Institute's patient education materials (NEI Diabetic Retinopathy).